Skip to main content

Advertisement

Log in

Compulsory licensing and access to drugs

  • Original Paper
  • Published:
The European Journal of Health Economics Aims and scope Submit manuscript

Abstract

Compulsory licensing allows the use of a patented invention without the owner’s consent, with the aim of improving access to essential drugs. The pharmaceutical sector argues that, if broadly used, it can be detrimental to innovation. We model the interaction between a company in the North that holds the patent for a certain drug and a government in the South that needs to purchase it. We show that both access to drugs and pharmaceutical innovation depend largely on the Southern country’s ability to manufacture a generic version. If the manufacturing cost is too high, compulsory licensing is not exercised. As the cost decreases, it becomes a credible threat forcing prices down, but reducing both access and innovation. When the cost is low enough, the South produces its own generic version and access reaches its highest value, despite a reduction in innovation. The global welfare analysis shows that the overall impact of compulsory licensing can be positive, even when accounting for its impact on innovation. We also consider the interaction between compulsory licensing and the strength of intellectual property rights, which can have global repercussions in other markets beyond the South.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Similar content being viewed by others

Notes

  1. This is why the terms access and coverage are used interchangeably in this article.

  2. Countries that do not meet their certain obligations are subject to trade penalties [20].

  3. For more details on the Brazilian case, see, for instance, http://www.cptech.org/ip/health/c/brazil/.

  4. Indonesia, India, Vietnam and South Korea have all threatened Roche with a compulsory license for Tamiflu, a commonly used drug for flu treatment. Roche decided to manufacture the drug with partners from these four countries [36].

  5. Compulsory licenses are used in a wider variety of cases, in both the patent and copyright areas. In the US, National Public Radio and PBS have a license as non-commercial institutions to play music on public broadcasting. In the biotech industry, the US government has granted a number of compulsory licenses on key patents to other biotech and pharmaceutical companies. The US government also uses compulsory licenses of air-pollution technology to promote clean air under the Clean Air Act. See http://www.cptech.org/ip/health/cl for more information and examples.

  6. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:157:0001:0007:EN:PDF.

  7. There are many factors that can weaken the ability of a drug company to adopt differential pricing globally. Even if parallel trade under compulsory licence is illegal, it does not mean it is not possible, especially if enforcement is weak. Hornbeck [18] finds evidence of illegal international smuggling of expensive AIDS drugs from African countries to the US.

  8. Preferences of this kind have been employed to describe pharmaceutical markets by Wright [38] and Valletti and Szymanski [35], among others, and can also be interpreted as stemming from income heterogeneity. Notice that we are therefore assuming that there are disparities of income in both the North and South. We avoid any reference to co-payment mechanisms, as these preferences are simply meant to generate downward demands in both countries: if the price of a drug decreases, more people will have access to it (either by paying in part or by having a health provider paying for it). Similarly, if the quality of a drug increases, ceteris paribus, there is a demand expansion effect. The model could easily be amended to include a third-party payer. This would not change the profit per unit for the supplier. The elasticity of demand for the drug would increase on the level of patients’ co-payment.

  9. As will become apparent below, the parameter restriction \(\frac{k}{a^{4}\sigma ^{2}}>\frac{1}{16C^{\prime \prime }}\) is needed for the second-order condition w.r.t. u to always be satisfied.

  10. One interpretation is the following. Imagine that, in the South, there is a certain mass of potential consumers who live in different locations, which are ordered according to a “distance” parameter x. This represents how easy or difficult it is to supply and market drugs at that location (e.g., geographic access). Consumers at x = 0 are those in the biggest city, where it is very easy to supply them (e.g., because basic services are already in place), while to reach, supply and administer drugs to more people in remote regions becomes progressively more expensive for the provider. The model will endogenously determine the equilibrium value of x, i.e., the coverage of those locations where people might have access to the drug.

  11. All proofs are in the “Appendix,” where also the expressions for the threshold value L, which determines the interval of validity of the region where CL is exercised, are derived.

  12. In Fig. 2, we use a quadratic cost function C(u) = u 2/2, and set k = 1, a = 1, σ = 1. While we frame the discussion in terms of F, one could similarly refer, e.g., to the equilibrium size of the South relative to the North, as described by k, after having fixed a value for the other parameters. What matters to distinguish the three regions of Proposition 1 is in fact simply the term Fk/(a 4 σ 2).

  13. Under a quadratic cost function \(C(u)=\frac{u^{2}}{2}\), it is \(u^{\ast }=\frac{4k}{16k-a^{4}\sigma ^{2}}\) and \(u^{N}=\frac{1}{4}\). Hence \(x^{{\rm CL}}=\frac{u^{N}a^{2}\sigma }{2k}>x^{\ast }=\frac{u^{\ast }a^{2}\sigma }{4k}\) for all values \(k>\frac{a^{4}\sigma ^{2}}{8}\).

  14. Instead of (6), the value of the outside option would now be \(W_{S}^{{\rm CL}}=\frac{\sigma ^{2}(a^{2}u^{2}-p_{S}^{2})^{2}}{8ku^{2}}-F,\) where p S is the solution to the break-even condition in the South \(\frac{\sigma ^{2}(au-p_{S})^{2}(3p_{S}-au)(p_{S}+au)}{8ku^{2}}-F=0.\)

  15. We observe here that the unrestricted case can arise from all sorts of leakages. For instance, this could happen when, under paragraph 6 of the Doha Declaration, a developed country manufactures a drug on behalf of a developing one, and the shipments of the drug to the developing country are not easy to monitor.

  16. This is a standard assumption in the literature on parallel trade. It is easy to accommodate imperfect arbitrage in the model, e.g., by having unit transportation costs t for parallel traders. In this case, if t is not large, p N  = p S  + t.

  17. Precisely because in region (iii), under a “restricted” regime, the good produced under CL in the South would not be reimported in the North, while in region (ii) the good produced by the monopolist (and not under CL) would be lawfully subject to parallel trade, the monopolist has a stronger incentive to let region (iii) emerge under parallel trade than without. This explains why the threshold values satisfy \(\widetilde{L}>L\), that is, the region where CL is exercised is wider under parallel trade.

  18. Recall that in order for the SOC to be satisfied, it must be k/(a 4 σ 2) > 1/16; hence, \(u^{\ast }>0\).

  19. The difference between marginal profits without and with parallel trade is \(\frac{(u-2p_{S})(2p_{S}^{3}-3p_{S}^{2}+u^{3})}{4u(u-p_{S})^{2}(u-4p_{S})}\), which is positive for all \(u/4<p_{S}<p^{\ast }\).

References

  1. Bale, H.E.: The conflicts between parallel trade and product access and innovation: the case of pharmaceuticals. J. Int. Econ. Law 1(4), 637–653 (1998)

    Article  Google Scholar 

  2. Bardey, D., Bommier, A., Jullien, B.: Retail price regulation and innovation: Reference pricing in the pharmaceutical industry. J. Health Econ. 29(2), 303–316 (2010)

    Article  CAS  PubMed  Google Scholar 

  3. Bennato, A.R., Valletti, T.: Pharmaceutical innovation and parallel trade. CEPR Discussion Paper (2011)

  4. Brekke, K., Königbauerb, I., Straume, O.R.: Reference pricing of pharmaceuticals. J. Health Econ. 26(3), 613–642 (2007)

    Article  PubMed  Google Scholar 

  5. Chaudhuri, S., Goldberg, P., Jia, P.: Estimating the effects of global patent protection in pharmaceuticals: a case study of quinolones in India. Am. Econ. Rev. 96, 1477–1514 (2006)

    Article  Google Scholar 

  6. Coco, R., Nebbia, P.: Compulsory licensing and interim measures in Merck: a case for Italy or for antitrust? J. Intellect. Prop. Law Pract. 2(7), 452–462 (2007)

    Article  Google Scholar 

  7. Cohen, J.: Expanding drug access in Brazil: lessons for Latin America and Canada. Can. J. Public Health 97(6), 15–18 (2006)

    Google Scholar 

  8. Cohen, J.: Brazil, Thailand override big pharma patents. Science 11, 816 (2007)

    Article  Google Scholar 

  9. Danzon, P.M.: Price discrimination for pharmaceuticals: welfare effects in the US and the EU. Int. J. Econ. Bus. 4(3), 301–321 (1997)

    Article  Google Scholar 

  10. Danzon, P.M., Towse, A.: Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int. J. Health Care Finance Econ. 3, 183–205 (2003)

    Article  PubMed  Google Scholar 

  11. Danzon, P.M., Wang, R., Wang, L.: The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ. 14(3), 269–292 (2005)

    Article  PubMed  Google Scholar 

  12. Galizzi, M., Ghislandi, S., Miraldo, M.: Effects of reference pricing in pharmaceutical markets: a review. PharmacoEconomics 29(1), 17–33 (2011)

    Article  PubMed  Google Scholar 

  13. Ganslandt, M., Maskus, K.E.: Parallel imports and the pricing of pharmaceutical products: evidence from the EU. J. Health Econ. 23, 1035–1057 (2004)

    Article  PubMed  Google Scholar 

  14. Garcia Mariñoso, B., Jelovac, I., Olivella, P.: External referencing and pharmaceutical price negotiation. Health Econ. 20(6), 737–756 (2011)

    Article  PubMed  Google Scholar 

  15. Goroff, M., Reich, M.: Partnership to provide care and medicine for chronic diseases: a model for emerging markets. Health Affairs 29(12), 2206–2213 (2010)

    Article  Google Scholar 

  16. Grossman, G.M., Lai, E.: Parallel imports and price control. RAND J. Econ. 39(2), 378–402 (2008)

    Article  Google Scholar 

  17. Guo, S., Hu, B., Zhong, H.: Impact of parallel trade on pharmaceutical firm’s profits: rise or fall? Eur. J. Health Econ. 14(2), 345–355 (2013)

    Article  PubMed  Google Scholar 

  18. Hornbeck, R.: Price discrimination and smuggling of AIDS drugs. Top. Econ. Anal. Policy 5(1), article 16 (2005)

    Google Scholar 

  19. Jelovac, I., Bordoy, C.: Pricing and welfare implications of parallel imports in the pharmaceutical industry. Int. J. Health Care Finance Econ. 5, 5–21 (2005)

    Article  PubMed  Google Scholar 

  20. Kerr, A.W., Gaisford, J.D.: Handbook on International Trade Policy. Edward Elgar Publishing Limited, UK (2007)

    Book  Google Scholar 

  21. Lybecker, K.M., Fowler, E.: Compulsory licensing in Canada and Thailand: comparing regimens to ensure legitimate use of the WTO rules. J. Law Med. Ethics 37(2), 222–239 (2009)

    Article  PubMed  Google Scholar 

  22. Mantovani, A., Naghavi, A.: Parallel imports and innovation in an emerging economy: the case of Indian pharmaceuticals. Health Econ. 21(11), 1286–1299 (2012)

    Article  PubMed  Google Scholar 

  23. Maskus, K.E.: Intellectual property rights in the global economy. Institute for International Economics, Washington, DC (2000)

  24. Matthews, D.: WTO Decision on Implementation of paragraph 6 of the DOHA Declaration on the TRIPs agreement and Public Health: a solution to the access to essential medicines problem? J. Int. Econ. Law 7(1), 73–107 (2004)

    Article  Google Scholar 

  25. Miraldo, M.: Reference pricing and firms’ pricing strategies. J. Health Econ. 28(1), 176–197 (2009)

    Article  PubMed  Google Scholar 

  26. Morais, R.: Parallel imports and price controls. Mimeo (2005)

  27. Mussa, M., Rosen, S.: Monopoly and product quality. J. Econ. Theory 18(2), 301–317 (1978)

    Article  Google Scholar 

  28. NHSO (2007) Facts and evidences on the 10 burning issues related to the government use of patents on three patented drugs in Thailand. The Ministry of Public Health and The National Health Security Office Thailand, National Health and Security Office

  29. Pecorino, P.: Should the US allow prescription drug reimports from Canada? J. Health Econ. 21, 699–708 (2002)

    Article  PubMed  Google Scholar 

  30. Pécoul, B., Chirac, P., Trouiller, P.: Access to essential drugs in poor countries—a lost battle? J. Am. Med. Assoc. 281, 361–367 (1999)

    Article  Google Scholar 

  31. Reichman, J.: The aims of health policy are often in conflict with those of economic trade. J. Law Med. Ethics 37(2), 247–263 (2009)

    Article  PubMed Central  PubMed  Google Scholar 

  32. Rozek, R.P.: The effects of compulsory licensing on innovation and access to health care. J. World Intellect. Prop. 3(6), 889–917 (2000)

    Article  Google Scholar 

  33. Scherer, F.M., Watal, J.: Post-TRIPS options for access to patented medicines in developing nations. J. Int. Econ. Law 5(4), 913–939 (2002)

    Article  Google Scholar 

  34. Steinbrook, R.: Thailand and the compulsory licensing of efavirenz. N. Engl. J. Med. 6, 544–546 (2007)

    Article  Google Scholar 

  35. Valletti, T., Szymanski, S.: Parallel trade, international exhaustion and IPRs: a welfare analysis. J. Ind. Econ. 54(4), 499–526 (2006)

    Article  Google Scholar 

  36. van Zimmeren, E., Requena, G.: Ex-officio licensing in the medical sector: the French model. In: Van Overwalle, G. (ed.) Gene Patents and Public Health, Bruylant, Brussels (2007)

  37. WHO (2002) Medicines strategy 2000–2003: framework for action in essential drugs and medicines policy, World Health Organization, Geneva

  38. Wright, D.: The drug bargaining game: pharmaceutical regulation in Australia. J. Health Econ. 23, 785–813 (2004)

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Charitini Stavropoulou.

Additional information

We thank the editor, two referees, Anton Giulio Manganelli, Marisa Miraldo and participants in the 2013 CRESSE conference for useful comments.

Appendix

Appendix

Proof of Proposition 1

In region (i), if F is high, the outside option is ineffective; thus, we obtain the same result as in the unregulated benchmark case, that is, \(u^{{\rm CL}}=u^{\ast }\), which therefore is valid as long as \(Fk/(a^{4}\sigma ^{2})>3(u^{\ast })^{2}/32\). The other limiting case is in region (iii) when F is very low, so that the firm never sells in the South; then π S  = 0, and quality is \(u=u^{N}<u^{\ast }\). This candidate solution is valid as long as Fk/(a 4 σ 2) < 37(u N)2/512. The analysis is more involved in region (ii), valid for intermediate values of F, the constraint identified by the threat of the government to use the outside option binds, which is re-written as

$$CS_{S}=\frac{u^{2}a^{4}\sigma ^{2}}{8k}-F\Rightarrow 4(au-p_{S})^{3}p_{S}\sigma ^{2}-u^{2}(a^{4}\sigma ^{2}u^{2}-8Fk)=0.$$
(11)

In the first stage, the firm solves

$$\frac{{\rm d}\varPi }{{\rm d}u}=\frac{\partial \varPi }{\partial u}+\frac{\partial \varPi }{ \partial p_{S}}\frac{\partial p_{S}}{\partial u}=0.$$
(12)

By means of implicit differentiation of (11), it is

$$\frac{\partial p_{S}}{\partial u}=\frac{\frac{\partial \frac{ u^{2}a^{4}\sigma ^{2}}{8k}}{\partial u}-\frac{\partial CS_{S}}{\partial u}}{ \frac{\partial CS_{S}}{\partial p_{S}}}=\frac{ (au)^{4}-2(au-p_{S})^{2}p_{S}(au+2p_{S})}{2u(au-p_{S})^{2}(au-4p_{S})}.$$
(13)

The numerator of (13) is always positive, as the expression 2(au − p S )2 p S (au + 2p S ) is single peaked in p S for p S  < au and even at the maximum can never exceed in absolute value (au)4. The denominator is always negative as we are in a range of prices between the unregulated benchmark and the preferred price for the South: au/4 < p S  < au/2. Thus, \(\frac{\partial p_{S}}{\partial u}<0,\) as an increase in u increases the value of the outside option relatively more; hence, the price must be decreased in order to make the South accept the offer. Since in (12) it is also \(\frac{\partial \varPi }{\partial p_{S}}=0\) for \(p_{S}=p_{S}^{\ast }\), and \(\frac{\partial \varPi}{\partial p_{S}}>0\) for all \(p_{S}<p_{S}^{\ast }\), we can then conclude that quality starts at \(u^{\ast }\) when \(Fk/(a^{4}\sigma ^{2})=3(u^{\ast })^{2}/32\) and then decreases monotonically as F becomes smaller and \(p_{S}<p_{S}^{\ast }\). The solution is found by looking, in the {p S u} space and within the admissible cone \(au/4<p_{S}<p_{S}^{\ast }\), at the highest isoprofit curve of the monopolist satisfying the constraint (11). It is easy to prove that there is always an interior solution strictly inside the cone. Although we omit the expressions for space limitation, this result is obtained because the isoprofit curves are vertical at \(p_{S}=p_{S}^{\ast }\) and then convex for lower prices, while instead the constraint is vertical at p S  = au/4 and then concave for higher prices; thus, there is always a tangency point. We can also prove that the monopolist chooses this solution as long as it makes at least the same amount as \(\frac{u^{N}}{4}-C(u^{N})\). In fact, as \(\left. \frac{\partial \varPi}{\partial u}\right\vert _{u=u^{N}}<0\) for low enough p S , we can show that it is optimal for the monopolist: (1) to push the interior solution for values of Fk/(a 4 σ 2) up to a limit value L strictly lower than 37(u N)2/512, where L is defined by the isoprofit curve \(\varPi =\frac{u^{N}}{4}-C(u^{N})\) subject to (11), and (2) it necessarily offers a quality below u N for values of Fk/(a 4 σ 2) approaching L from above.

Results on coverage follow easily by noting that in region (iii) it is x CL = u N a 2 σ/2k. When instead we are in the intermediate region (ii), then from (4) it is \(x^{{\rm CL}}<x^{\ast }=u^{\ast }a^{2}\sigma /4k\). As we have just established that, when Fx/(a 4 σ 2) approaches L from above, u < u N, for sure coverage jumps up when Fx/(a 4 σ 2) is further reduced and CL is exercised in region (iii) (with autarky it would be x N = 0). In fact, it may even be that coverage in region (iii) is higher than in region (i) where it is \(x^{{\rm CL}}=u^{\ast }a^{2}\sigma /4k\). This arises when u N a 2 σ/2k > \(u^{\ast }a^{2}\sigma /4k\), or \(u^{\ast }<2u^{N}\), which depends on the convexity of the cost function C(u) and on the value of k. The inequality is always satisfied when k is large enough, as in the limit \(u^{N}\rightarrow u^{\ast }\). □

Proof of Proposition 2

When \(C(u)=\frac{u^{2}}{2}\), it is \(u^{\ast }=\frac{4k}{16k-a^{4}\sigma ^{2}}\), Footnote 18 as well as \(p^{N}=\frac{u^{\ast }}{2},p^{S}=\frac{au^{\ast }}{2}\) and \(x^{\ast }=\frac{u^{\ast }a^{2}\sigma }{4k}\). These can be substituted in (9) to obtain

$$W^{\ast }=\frac{k(32k-3a^{4}\sigma ^{2})}{2(16k-a^{4}\sigma ^{2})^{2}}.$$

In region (iii), it is \(u^{N}=\frac{1}{4}\), and \(p^{N}=\frac{u^{N}}{2},p^{S}=0, x^{{\rm CL}}=\frac{u^{N}a^{2}\sigma }{2k}\). From (10) we compute

$$W^{{\rm CL}}=\frac{8k+a^{4}\sigma ^{2}}{128k}-F.$$

When \(F \rightarrow 0\) it is always \(W^{{\rm CL}}>W^{\ast }\) for all admissible values of k/(a 4 σ 2) > 1/16. The result is in fact stronger and extends to the entire region (iii). This is because, from Proposition 1, in region (iii) it must be Fx/(a 4 σ 2) < L < 37(u N)2/512, and therefore F is bounded above by 37(u N)2 a 4 σ 2/(512k). Even at this higher threshold, it is immediate to show that \(W^{{\rm CL}}>W^{\ast }\) for all admissible values of k/(a 4 σ 2). □

Proof of Proposition 3

Let us start with the restricted case, where goods produced in the South under CL cannot be reimported, whereas those supplied by the monopolist can. If F is high, the outside option is ineffective, \(p=p^{\ast }\) is set everywhere; thus, we obtain the same result as without parallel trade (identical to the unregulated benchmark case). If F is very low, the firm never sells in the South (which recurs to CL) but can set \(p_{N}=p^{\ast },\) so that π S  = 0 and π N  = u/4, and quality is again as in the case without parallel trade. If F is intermediate, then π N  = p S (1 − p S /u) and π S  = p 2 S (u − p S )2/2ku 2. Like in the proof of the previous proposition, the solution is found by looking at the highest isoprofit curve (8) satisfying the constraint (11). The constraint is the same, with and without parallel trade, and it is still characterized by ∂p S /∂u < 0. Since it is easy to prove that parallel trade reduces the marginal revenue, Footnote 19 we thus obtain that the effect of parallel trade is to reduce investment and increase the price cap. Another difference with the case without parallel trade is that, while the monopolist still pushes this interior solution for values of Fk lower than 37(u NC)2/512, now profits when both countries are supplied are strictly lower than without parallel trade (they coincide only when \(p_{S}=p^{\ast }\)); thus, the monopolist stops supplying the South for values below \(\widetilde{L}\), which is strictly higher than L, and again defined by the isoprofit curve \(\varPi =u^{N}/4-C(u^{N})\) subject to (11).

We now turn our analysis to the case of “unrestricted parallel trade.” The good manufactured in the South will be exported and traded everywhere, also under the compulsory licensing regime (i.e., by means of the gray market). Cases (i) and (ii) are unchanged and do not need to be analyzed again. The difference is that now the monopolist will never withdraw from the South; hence, CL will never be used along the equilibrium path. If it did so, then the price in the South would be zero but would apply everywhere, and the monopolist would not invest at all. Therefore, the validity of region (ii) is now extended also for all values below \(\widetilde{L}\). Investment approaches zero, as well as prices and coverage, only as \(F\rightarrow 0\). □

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stavropoulou, C., Valletti, T. Compulsory licensing and access to drugs. Eur J Health Econ 16, 83–94 (2015). https://doi.org/10.1007/s10198-013-0556-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10198-013-0556-2

Keywords

JEL Classification

Navigation